Introduction
Studies in the 1950s indicated that death attributable to hematopoietic damage caused by ionizing radiation can be prevented by pretreatment with immunomodulatory agents (1) . Such agents were recognized to stimulate the reticuloendothelial system, but their mechanism of action has not been well defined. The subsequent finding that proinflammatory This paper is based on a presentation at the International Conference on Radiation and Health held 3-7 November 1996 in Beer Sheva, Israel. Abstracts of these papers were previously published in Public Health Reviews 24 (3) (4) : 205-431 (1996) . Manuscript received at EHP 18 April 1997; accepted 2 July 1997.
Address correspondence to Dr. R. Neta, Office of International Health Programs, U.S. Department of Energy, 19901 Germantown Rd, Germantown, MD 20874. Telephone: (301) . Fax: (301) 903- 1413. E-mail: ruth.neta@eh.doe.gov Abbreviations used: cGy, centigray; EPO, erythropoietin; 5-FU, 5-fluorouracil; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocytemacrophage colony-stimulating factor; Gy, gray; HU, hydroxyurea; IFN, interferon; IL, interleukin; M-CSF, macrophage colony-stimulating factor; NFiB, nuclear factor KB; SCF, stem-cell factor; TGF, transforming growth factor; TNF, tumor necrosis factor; TPO, thrombopoietin.
cytokines can confer radioprotection (2) facilitated a more direct approach to study such mechanisms of protection.
Cytokines produced by stimulated cells and tissues are hormonelike proteins that serve in either autocrine, paracrine, and at times, endocrine fashion, as intercellular messengers. A number of cytokines: interleukin-1 (IL-1), tumor necrosis factor (TNF), and IL-6 stimulate a broad range of cell and tissue activities (3). These diverse effects depend on the type of signaling receptor and on components of the signal transducing pathway engaged in a given cell, which leads at times to the subsequent activation of different transcription factors. For example, it was recently found that upregulation or the lack of upregulation of the nuclear factor KB (NFKB) lead to a seemingly paradoxic observation-that TNF may lead to apoptosis of some cells yet induce proliferation or differentiation of others (4) .
As the characteristics and modes of action of cytokines are becoming rapidly understood, the basis for their protective and/or restorative action is being delineated and should aid in developing a better understanding of the role of inflammatory pathways in producing radiation damage and of protection against such damage. Such understanding should lead to the development of a more optimal treatment aimed at preventing damage to normal tissues.
Preclinical and clinical studies demonstrated that a broad range of cytokines can serve to accelerate bone marrow restoration following myeloablative cytotoxic drugs or radiation (5) . Although many of these cytokines such as IL-3, granulocyte colony-stimulating factor (G-CSF), This paper briefly reviews several of our findings: a) evidence for an important role that IL-1, TNF, IL-6, and SCF play in innate defenses against ionizing radiation; b) evidence that cytokines act in a network, i.e., following cytokine administration to a host, a cascade of additional cytokines and other mediators are induced at different times leading to different outcomes depending on the treatment regimen; and c) evidence that the same cytokine may have opposing effects on different tissues.
Cytokines in Radioprotection and Innate Resistance to Radiation
Administration of cytokines IL-1, TNF, SCF, or given within 18 to 24 hr before irradiation protects mice from death. Conversely, anti-IL-1, anti-TNF antibodies, and anti-SCF antibodies in mice not treated with cytokines resulted in LD50/30 doses of radiation becoming lethal to 100% of mice, indicating that the endogenous production of each of these cytokines contributes to innate radiation tolerance (7, 8 (8, 9) . Furthermore, the antibody to the IL-1 receptor blocked TNF-induced radioprotection, whereas t4e antibody to the TNF blocked IL-1-induced radioprotection. The antibody to SCF blocked IL-1 and TNF induced radioprotection, whereas the antibody to the IL-1 receptor blocked SCF radioprotection. IL-1 also synergized with IL-6, GM-CSF, and G-CSF. However, since IL-1 induces the production of all three of these cytokines, this synergy could be observed only at suboptimal radioprotective doses of IL-1. Thus, the contribution of numerous cytokines to radioprotection seems to be a prerequisite for optimal radioprotection. Each of these cytokines was shown to be upregulated after animal exposure to ionizing radiation (10) Gastrointestinal Tissues IL-12 has potent antitumor and antimetastatic activity in a number of murine tumor models (15) . This property, along with the observation that it is a stimulator of the early hematopoietic progenitor cells, suggest that in addition to playing an important role in cancer therapy IL-12 may act as a myeloprotector. Indeed, administration of IL-12 within 24 hr before otherwise lethal irradiation protected a significant fraction of mice from lethal hematopoietic syndrome (16) . The radioprotection was associated with a significant increase in the numbers of hemopoietic progenitor cells found in marrow 3 days after administration of 1200 cGy. IL-12, however, radiosensitized, not radioprotected, the gastrointestinal tract as evidenced in mice that died within 4 to 6 days after receiving IL-12 and 1200 cGy. The gastrointestinal syndrome was documented by gross necroscopy and histologic evaluation. Induction of a similar syndrome in mice not treated with IL-12 required doses greater than 1600 cGy. Thus, at doses of radiation at which IL-12 still protects bone marrow cells, it sensitizes the intestinal tract to radiation damage. Although protection of hematopoietic cells was abrogated with anti-IL-lR and anti-SCF antibody, sensitization of the intestinal tract was prevented with anti-IFNy and anti-TNF antibody (15 
Conclusions
Complete understanding of how cytokines are radioprotective at the cellular level will only be achieved when we understand how the irradiated cells die. Apoptotic death is presumed to occur in hematopoietic stem cells. There is little direct information about the radiation-induced apoptotic process in these cells because they are rare cells in the host tissues, and culturing them outside the host environment requires conditions that probably are not physiological.
Several possible mechanisms of radioprotection by cytokines have emerged: a) reduction of oxidative damage through induction of mitochondrial enzymes such as MnSOD, and other scavenging proteins, as demonstrated for IL-1, TNF, and IL-6; b) reduction of apoptotic response through induction of bcl-2 by SCF; and c) induction of normally quiescent early progenitor cells to enter the cell cycle and possibly reach the relatively radioresistant late S-phase, as suggested by the kinetics of IL-I and SCF radioprotection and the susceptibility these cells develop to cycle-dependent drugs HU and 5-FU.
In contrast, the sensitizing mechanisms may include: a) increased oxidative damage that may occur in the absence of scavenger induction, as observed for TNF for many tumor cell line; b) enhanced apoptosis by upregulation of Fas antigen, as reported for TNF and IFN'y or activation of hydrolysis of sphingomyelin to ceramide and subsequent downregulation of bcl-2 mRNA expression; and c) arrest of cells in G1 phase of the cycle at the time of exposure to radiation, which may promote apoptosis. Although not completely understood, the growth-arresting effect of TGF-f may be exerted on several molecular targets (14) . Among the suggested targets are downregulation of c-myc RNA and protein levels, downregulation of transcriptional induction of cyclin A and cyclin E, and upregulation of inhibitors for cdk-cyclin complexes, p15, p16, p21 and p27. Evidence accumulating from different cell types suggests that there may be substantial differences between different cells in the mechanisms by which TGF-, inhibits their proliferation.
